Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C O Tacket

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Infection and Immunity|June 1, 1996
New evidence for an inflammatory component in diarrhea caused by selected new, live attenuated cholera vaccines and by El Tor and Q139 Vibrio choleraeT M Silva, M A Schleupner, C O Tacket, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|January 1, 1995
Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen OC O Tacket, G Losonsky, J P Nataro, et al.
The Journal of Infectious Diseases|October 1, 1992
Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgRC O Tacket, G Losonsky, J P Nataro, et al.
The Journal of Infectious Diseases|December 1, 1994
Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhiM B Sztein, S S Wasserman, C O Tacket, et al.
Vaccine|January 1, 1993
Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide)R Edelman, R G Russell, G Losonsky, et al.
Lancet (London, England)|August 27, 1988
Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgRM M Levine, J B Kaper, D Herrington, et al.
Infection and Immunity|February 7, 1998
Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infectionC O Tacket, R K Taylor, G Losonsky, et al.
Infection and Immunity|August 1, 1997
Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector systemC O Tacket, S M Kelly, F Schödel, et al.
The Journal of Infectious Diseases|April 1, 1995
Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteersJ G Morris, G E Losonsky, J A Johnson, et al.
The Journal of Infectious Diseases|September 1, 1995
Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challengeC O Tacket, G Losonsky, J P Nataro, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Infection and Immunity|June 1, 1996
New evidence for an inflammatory component in diarrhea caused by selected new, live attenuated cholera vaccines and by El Tor and Q139 Vibrio choleraeT M Silva, M A Schleupner, C O Tacket, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|January 1, 1995
Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen OC O Tacket, G Losonsky, J P Nataro, et al.
The Journal of Infectious Diseases|October 1, 1992
Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgRC O Tacket, G Losonsky, J P Nataro, et al.
The Journal of Infectious Diseases|December 1, 1994
Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhiM B Sztein, S S Wasserman, C O Tacket, et al.
Vaccine|January 1, 1993
Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide)R Edelman, R G Russell, G Losonsky, et al.
Lancet (London, England)|August 27, 1988
Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgRM M Levine, J B Kaper, D Herrington, et al.
Infection and Immunity|February 7, 1998
Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infectionC O Tacket, R K Taylor, G Losonsky, et al.
Infection and Immunity|August 1, 1997
Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector systemC O Tacket, S M Kelly, F Schödel, et al.
The Journal of Infectious Diseases|April 1, 1995
Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteersJ G Morris, G E Losonsky, J A Johnson, et al.
The Journal of Infectious Diseases|September 1, 1995
Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challengeC O Tacket, G Losonsky, J P Nataro, et al.
Pageof 9